VIMTALABSNSEVimta Labs Limited· PharmaceuticalsHighNeutral
Announced Wed, 6 May · 16:00 IST

Audited Financial Results for the 4TH Quarter and Financial Year ended 31.03.2026

Revenue Growth 20pctPat Growth 25pctResults View source PDF

VIMTALABS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+0.5%1-day move
₹510.70
prior close
₹529.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+7.5+4.8+4.0+2.2+0.5-3.7-8.3-8.5-10.3-13.1-7.4+2.4+8.2
Up moveDown movePending
AI summary

Vimta Labs Limited reported audited financial results for FY2025-26 with total income of Rs 4,162.79 million, up 19.6% from Rs 3,482.22 million in the previous year. Revenue from operations grew 18.4% to Rs 4,072.90 million. Profit after tax from continuing operations increased to Rs 775.12 million from Rs 667.55 million, representing 16.1% growth. The company also completed a bonus share issue in 1:1 ratio during the year. Statutory auditors issued an unmodified (clean) opinion. The board recommended a dividend of Rs 2 per share and approved setting up a wholly owned subsidiary in the USA. The diagnostic business sold to Thyrocare contributed Rs 5.87 million to total profit after tax.

Likely market impact

Strong revenue and profit growth with clean audit opinion signals healthy operational performance. The bonus issue and dividend recommendation are positive for shareholders. Expansion plans via USA subsidiary may require monitoring for capital deployment impact.